JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating

JMP Securities analyst Reni Benjamin maintains $Inhibrx Biosciences(INBX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 33.0% and a total average return of -9.8%

Moomoo News01:31 ET · Ratings

Inhibrx Biosciences: Hold Rating Justified by Financial Stability and Clinical Pipeline Potential

TipRanks00:35 ET

Inhibrx Biosciences Files to Sell 2.45M Shares of Common Stock for Holders

Seeking AlphaJun 11 17:23 ET

Inhibrx Biosciences(INBX.US) Director Buys US$997.02K in Common Stock

$Inhibrx Biosciences(INBX.US)$ Director Kayyem Jon Faiz purchased 57,549 shares of common stock on Jun 5, 2024 at an average price of $17.32 for a total value of $997.02K.Source: Announcement What is

moomoo NewsJun 7 18:45 ET

Express News | Inhibrx Biosciences 13G Filing Shows Viking Global Investors LP Reported A 12.3% Stake In The Co As Of May 29, 2024

BenzingaJun 7 16:29 ET

Express News | Viking Global Investors LP Reports 12.3% Passive Stake in Inhibrx Biosciences, Inc. as of May 29, 2024- SEC Filing

ReutersJun 7 16:27 ET